C
Cagent Vascular
Device used in angioplasty to treat cardiovascular disease
About Cagent Vascular
Cagent Vascular is a medical device company that has developed a proprietary serration technology for the treatment of peripheral artery disease (PAD). The company's flagship product is the Serranator® Alto and Serranator® Bass PTA Serration Balloon Catheters, which are designed to create multiple longitudinal lines of interruption in the arterial wall to aid in arterial expansion and lumen gain. This technology is intended to provide a more controlled and predictable dilatation of stenotic lesions in the peripheral arteries, which may lead to improved clinical outcomes for patients with PAD.
Read full description
The company's business model is focused on the development and commercialization of its serration technology. Cagent Vascular generates revenue through the sale of its Serranator® balloon catheter products to hospitals and other healthcare providers that perform peripheral artery interventions. The company operates in the medical device market, specifically in the segment of devices for the treatment of cardiovascular diseases. Its target clients are interventional cardiologists, vascular surgeons, and other physicians who treat patients with PAD.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Radnor Township, United States
- Employees
- 93
- Open positions
- None listed
- Dealroom signal
- 90.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Non-Invasive medical devices and treatments, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Cagent Vascular.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | May 2026 | $41M | $164M | Astoria Health Investors · U.S. Venture Partners | ↗ |
| DEBTDebt | Feb 2025 | $15M | — | Trinity Capital | ↗ |
Growth signals
Latest recorded traffic for Cagent Vascular is 4.2K monthly website visits, up 100% over the last three months. Cagent Vascular's team grew 17.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Ben Franklin Technology Partners of Southeastern Pennsylvania
Series A1 investor entered at this stage
- SVSynergy Ventures
Series B and later5 investors entered at this stage
- BMBlue Ridge Medical
U.S. Venture Partners
Sectoral Asset Management
Trinity Capital- AIAstoria Health Investors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cagent Vascular on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cagent Vascular’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.